NL-OMON40213撤回不适用
Metabolic Syndrome Study. Renal Sympathetic Denervation for Treatment of Metabolic Syndrome Associated Hypertension - Metabolic Syndrome Study
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Patient with office blood pressure *140/90 mmHg and 24-hour ambulatory blood pressure *130/80 mmHg at Enrollment despite treatment with two drugs at maximum tolerated doses
- •- Patient with a fasting glucose *100 mg/dL (*5.6 mmol/L) at Enrollment
- •- Patient with a waist circumference *102 cm (*40 inches) for male or *88 cm (*35 inches) for female at Enrollment
- •- Patient with any of the other metabolic syndrome diagnostic criteria listed as follows at Enrollment:
- •o Triglycerides *150 mg/dL (*1.7 mmol/L) or on drug treatment for elevated triglycerides
- •o High density lipid cholesterol (HDL-C) <40 mg/dL (<1.03 mmol/L) for male or <50 mg/dL
- •(<1.30 mmol/L) for female or on drug treatment for reduced HDL-C
- •- Patient is *18 and *80 years old
- •- Patient must be able and willing to provide written informed consent to participate in this clinical investigation
- •- Patient must be able and willing to comply with the required follow-up schedule
排除标准
- •* Patient with resistant hypertension or secondary hypertension
- •* Patient with type I diabetes mellitus or type II diabetes mellitus requiring insulin therapy
- •* Patient with prior renal angioplasty, renal denervation, indwelling renal stents and/or
- •aortic stent grafts
- •* Patient with renal arteries <4.0 mm in diameter
- •* Patient with significant renovascular abnormalities (such as renal artery stenosis >30%)
- •* Patient with an estimated glomerular filtration rate (eGFR) of <45 mL/min per 1.73 m2
- •using the Modified Diet in Renal Disease (MDRD) formula
- •* Patient with hemodynamically significant valvular heart disease, as determined by Study
- •Investigator
- •* Patient has had a myocardial infarction, unstable angina pectoris or cerebrovascular
- •accident less than 180 days at Enrollment or is expected to have cardiovascular
- •intervention within the next 180 days
- •* Patient is in chronic atrial fibrillation/flutter or with severe conduction abnormalities or
- •with an implantable cardioverter defibrillator (ICD) or pacemaker whose settings cannot
- •allow for radiofrequency (RF) energy delivery
- •* Patient is currently being treated with drugs that cause salt retention (such as systemic
- •corticosteroids or fludrocortisone)
- •* Patient with an active systemic infection or blood-clotting abnormalities
- •* Patient is pregnant or of childbearing potential and is not using adequate contraceptive
- •methods or nursing
- •* Patient is participating in another clinical investigation
- •* Patient has a life expectancy less than 12 months, as determined by Study Investigator
- •* Patient has an allergy for contrast agent used for the angiogram
研究者
相似试验
撤回
不适用
Metabolic Syndrome Study. Renal Sympathetic Denervation for Treatment of Metabolic Syndrome.Metabool SyndroomMetabolic Syndrome - insulin resistance syndrome10057166NL-OMON41209St. Jude Medical15
已完成
不适用
Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)Metabolic SyndromeNCT01911078Abbott Medical Devices20
撤回
4 期
Renal Sympathetic Denervation in patients with therapy-resistant Catecholamine Polymorphic Ventricular Tachycardia (CPVT) and Long QT Syndrome (LQTS) * RESIDENT StudyNL-OMON41010Academisch Medisch Centrum20
撤回
4 期
Renal Sympathetic Denervation after Renal Transplantation Study - I10057166HypertensionNL-OMON37506eids Universitair Medisch Centrum10
已完成
3 期
Denervation of the REnal Artery in Metabolic SyndromeBlood PressureInsulin ResistanceNCT01465724UMC Utrecht29